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Introduction
Mutation of lymphoid progenitor cells in 
the bone marrow which induces excessive 
and uncontrolled lymphoid cell proliferation 
causes acute lymphoblastic leukemia (ALL).1 
Acute lymphoblastic leukemia is the most 
common leukemia diagnosed in children with 
the highest prevalence of rate in children 
aged 2–5 years old and predominantly in 
boys.2,3,4 Twenty-six percent of all malignancy 
cases diagnosed in the USA in 2014 is acute 
lymphoblastic leukemia.3 It is also one of 
the malignancies with high incidence rate 
in Indonesia, as shown in Dr. Hasan Sadikin 
General Hospital reports where fifty-one new 
cases of ALL had been found in 2010–2011, 
while 76 new cases were found in 2014.5,6 It 
is known that half of the pediatric patients 
with malignancy in 2006 had been admitted 
to Dharmais National Cancer Hospital with 
advanced stage condition. Lack of knowledge 
about any signs or symptoms of the disease 
has been the cause of such conditions.7 
Clinical features presenting in ALL are 
various. Generally, the first signs and symptoms 
are often non-specific which caused by anemia, 
such as irritability, anorexia, weakness, and 
pallor. Fever and infection might occur due to 
neutropenia, while thrombocytopenia might 
cause hemorrhages. Leukemic cells could 
infiltrate various organs resulting in other 
clinical features including hepatomegaly, 
splenomegaly, lymphadenopathy, and even 
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Abstract
Background: Acute lymphoblastic leukemia (ALL) is a disease caused by a mutation of lymphoid 
progenitor cells in bone marrow, that induces uncontrolled lymphoid cell proliferation. ALL is the 
most common type of leukemia in children. Various clinical and laboratory manifestation makes 
the diagnostic process more complicated. This study aimed to observe the clinical and laboratory 
manifestation of children with ALL in Dr. Hasan Sadikin General Hospital for diagnostic and assessment.
Methods: The design of this study was a descriptive cross-sectional with a total sampling method. Data 
of all children under 18 years old with ALL diagnosed in 2015 to 2017 were included. The diagnosis of 
ALL was confirmed by examination of hematology indices, peripheral blood smear, and bone marrow 
aspiration classified by FAB. Inaccessible or incomplete medical records were excluded.
Results: In total, 192 data of ALL patients were included. Most ALL patients predominantly occurred 
in boys (59.9%), and the age group of 1–5 years old (40.6%). The clinical manifestations were pallor 
(89.6%), hepatomegaly (79.7%) and fever (75%). Most patients experienced severe anemia with 
hemoglobin level <7g/dL (44.8%), leukocytosis >20.000 cells/mm3 (46.9%), severe thrombocytopenia 
with platelet count <20.000 cells/mm3 (51%), and blast cells count >50% (45.3%). Based on FAB 
classification, the majority of the patients were classified as ALL type L2 (65.6%).
Conclusions: Clinical and laboratory manifestation of ALL patients can be used as a parameter for 
diagnostic and assessment of severity. Earlier diagnosis would result in better prognosis and more 
precise treatment for ALL patients.
Keywords: Acute lymphoblastic leukemia, ALL, severity
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nerve involvement.4
Diagnosis and classification ALL can be 
determined based on clinical and laboratory 
examination. Data supporting diagnosis can 
be obtained from peripheral blood smear 
examination or bone marrow aspiration.8 
Early signs of ALL can be observed as 
abnormal blood examination, which is anemia, 
thrombocytopenia, and leukocytosis. Blast 
cells commonly found in the peripheral blood 
smear. Bone marrow aspiration acts as the 
gold standard in diagnosing ALL. When bone 
marrow aspiration result shows more than 5% 
of blast cells count, we can presume the patient 
as having leukemia; while for ALL definite 
diagnosis, more than 20% on blast cells count 
is needed. Differentiation of ALL and AML will 
be determined by cell morphology obtained 
from bone marrow aspiration classified 
based on French American British (FAB) 
classification. This classification depends on 
cell size, chromatin, nucleoli, and cytoplasm.4 
Classification based on the World Health 
Organization (WHO) can be done if the sample 
is examined using molecular method and then 
flow cytometri.9 Dr. Hasan Sadikin General 
Hospital’s procedure for diagnosing ALL 
consists of anamnesis, physical and laboratory 
examination such as hematology indices, 
peripheral blood smear, and bone marrow 
examination.5
Data on clinical and laboratory manifestation 
of ALL in children in Dr. Hasan Sadikin General 
Hospital Bandung is still unknown. Aim of 
this study was to give more information on 
clinical and laboratory manifestation of ALL in 
children in Dr. Hasan Sadikin General Hospital 
Bandung. This information could help in 
detecting and diagnosing ALL leading to more 
precise treatment and better prognosis.
Methods
The design of this study was a descriptive 
cross-sectional study. Data were obtained 
from inpatient Medical Record Unit Dr. Hasan 
Sadikin General Hospital Bandung during 
2015–2017. Subjects were all medical records 
of children who had been diagnosed with ALL 
for the first time in Dr. Hasan Sadikin General 
Hospital and confirmed with hematology 
examination, peripheral blood smear, and 
bone marrow aspiration, with total sampling 
method. Exclusion criteria were inaccessible 
or incomplete medical records. 
Clinical manifestations data was collected, 
including pallor, fever, hemorrhage, seizure, 
infiltrative presentation (hepatomegaly, 
splenomegaly measured by schuffner 
line which depends on enlargement 
of spleen measured from left costal margin 
to right anterior superior iliac spine, and 
lymphadenopathy); as well as and laboratory 
data, including hematological examination 
(hemoglobin, leukocyte, thrombocyte), 
peripheral blood smear for blast cell counting, 
and bone marrow aspiration to classify ALL 
based on FAB classification, depending on 
morphological including cell size, chromatin, 
nucleoli, and cytoplasm.4
Data were obtained from the medical 
record after Ethical Clearance was granted, 
issued by the Research Ethics Committee of 
Universitas Padjajaran Bandung (No. 219/
UN6.KEP/EC/2018) and Research Licensing 
Letter issued by the Research Ethics Commitee 
of Dr. Hasan Sadikin General Hospital Bandung 
(No. LB.02.01/X.2.2.1/9373/2018.) Data were 
presented in tables.




     Boy 115 59.9
     Girl 77 40.1
Age
     < 1 year old 7 8.9
     > 1–5 years old 78 40.6
     > 5–10 years old 56 29.2
     > 10–18 years old 41 21.4
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Results
There were 192 subjects from 284 medical 
records complying inclusion criteria. Most 
of the excluded medical records were due to 
inaccessibility or insufficiency data.
As shown in Table 1, the highest incidence 
rate occurred in boys (155 patients, 59.9%) 
and children with age category of >1–5 years 
old (78 patients, 40.6%). 
The clinical features of ALL were shown 
in Table 2. Pallor was the most common 
presenting complaint (n172;89.6%), followed 
by fever (n144; 75%). As for clinical findings, 
hepatomegaly was mostly found (n 153; 79.7%), 
classified into less than 5 cm enlargement 
group (n117;60.9%), while hemorrhage 
was mostly seen as skin manifestations 
(n63;32.8%). Lymph node enlargement was 
found (n131; 68.2%) with cervical as the most 
affected area; and Schuffner I-II, as the most 
common grade of splenomegaly, was detected 
(n72; 37.5%).
Severe anemia (Hb<7 g/dL) was seen (n86; 
44.8%), where asleucocytosis was found 
(n90; 46.9%). Most patients (n98; 51%)







     Gum 44 22.9
     Epistaxis 27 14.1
     Skin 63 32.8
     GI Tract 15 7.8
     Intracranial 1 0.52
     Eye 5 2.6
     Urinary Tract 2 1
     Others 9 4.7
Seizure - -
Lymphadenopathy
     Cervical 131 68.2
     Axillary 22 11.5
     Inguinal 36 18.8
     Others 3 1.6
Hepatomegaly
     < 5cm 117 60.9
     5–10 cm 34 17.7
     >10cm 2 1
Splenomegaly
     Schuffner I-II 72 37.5
     Schuffner III-IV 49 25.5
     Schuffner V-VI 2 1
     Schuffner VII-VIII - -
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were classified into severe thrombocytopenia 
group. Blast cell count >50% acquired from 
peripheral blood smear examination was also 
found (n 87; 45.3%) as shown in Table 3.
Furthermore, there were 33 samples of 192 
ALL patients whose bone marrow aspiration 
(BMA) classification based on FAB was not 
listed in the medical records. For further 
classification, 2 patients were classified as 
bilineage leukemia, 2 as early phase leukemia, 
and 3 others as preleukemia. The most common 
type of ALL based on FAB classification was 
L2 (n 126; 65.6%), whereas L1 and L3 were 
found in 21 (10.9%) and 5 (2.6%) patients, 
respectively.
Discussions
Our study has shown that acute lymphoblastic 
leukemia (ALL) has been predominantly 
occurred in boys and children aged >1– 5 years 
old, consistent with several previous studies in 
some parts of the world as reported from the 
USA and Southern China.10,11
Acute lymphoblastic leukemia patients 
have various clinical features. Infiltration of 
blast cells to bone marrow would suppress 
normal cell proliferation which caused varied 
presentations in each patient. The earliest 
manifestations are caused by anemia resulting 
in pallor and weakness, thrombocytopenia 
resulting in bleeding, and neutropenia 
resulting in fever.4 Pallor, hepatomegaly, 
and fever are found to be the most common 
presenting clinical manifestation of ALL. This is 
consistent with findings from previous studies 
that fever, pallor, and hepatosplenomegaly are 
the main presenting complaints of ALL.12,13
In addition to their infiltration to bone 





     < 7 86 44.8
     7–9.9 73 38
     10–10.9 16 8.3
     ≥11 17 8.9
Leukocyte(cells/mm3)
     <10,000 76 39.6
     10,000–20,000 26 13.5
     >20,000 90 46.9
Thrombocyte (cells/mm3)
     <20,000 98 51
     20,000-50,000 58 30.2
     >50,000-100,000 21 10.9
     >100,000-150,000 8 4.2
     >150,000 7 3.6
Blast cell count
     <20% 50 26
     20–50% 55 28.6
     >50% 87 45.3
Bone Marrow Aspirations L1 21 10.9
L2 126 65.6
L3 5 2.6
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marrow, leukemic cells also infiltrate other 
organs. Spleen, liver, and lymph nodes are the 
most common infiltrated organs.4 As seen in 
this study where hepatomegaly, splenomegaly, 
and lymphadenopathy are commonly 
presented in ALL patients. Similarly, reported 
in Iran, where main extramedullary symptoms 
are splenomegaly, followed by hepatomegaly 
and lymphadenopathy.14
Blood examinations in ALL patients will 
commonly show anemia, thrombocytopenia, 
and leukocytosis. These abnormalities are 
due to uncontrolled and excessive lymphoid 
cell proliferation and blast cells infiltrations 
to bone marrow which caused suppression 
of normal cell proliferation.4 As shown in 
this study, most of the patients have severe 
anemia (<7g/dL). These findings are similar 
to other reports where a large proportion 
of ALL patients are classified for having 
severe anemia.12,15 Leukocytosis is commonly 
presented in ALL patients. Similarly to the 
findings in Iran and Brazil, where most 
patients have leukocytosis.14,16 The majority of 
the patients have severe thrombocytopenia or 
decreased platelet count.17 Similarly founded 
in Brazil where the majority of their ALL 
patients have thrombocytopenia.15
The differentiation process of lymphoid 
cells is blocked in ALL patients, while their 
production and proliferation are uncontrolled, 
which result in blast cells findings in peripheral 
blood smear and bone marrow. ALL can be 
presumed with blast cells count results >5%, 
however for definite diagnosis of ALL, 20% 
blast cells or more is needed.4 Based on the 
result from peripheral blood smear, a large 
proportion of ALL patients have >50% of blast 
cells. This result was in sync with another 
study in Indonesia which reported that in 
almost ALL cases, peripheral blood smear 
would present higher blast cells count.17 Based 
on this study, the majority of the patients 
classified as L2 type. Similarly found in Eastern 
Iraq and India, where the most dominant type 
was L2, followed by L1 and L3.12,18
The limitation of this study was inaccessible 
medical record data or incomplete data which 
caused data to be excluded, resulting in a lower 
sample population.
To conclude, acute lymphoblastic 
leukemia(ALL) cases predominantly occur 
in boys and children between 1-5 years old. 
Pallor, hepatomegaly, and fever are the main 
presenting clinical features, while the most 
common laboratory features found in children 
with ALL are severe anemia, leukocytosis, and 
severe thrombocytopenia, with blast cells count 
>50%. ALL L2 is the most common type of ALL 
based on FAB classification. By understanding 
clinical and laboratory manifestation of ALL, 
this will help in the diagnosis and assessment 
of severity which, and thus better prognosis 
and more precise treatment.
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